Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSL1 | P33121 | 7/20 | 1.00 |
| ▸ | ACSL6 | Q9UKU0 | 3/20 | 1.00 |
| ▸ | ACSL3 | O95573 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 3/20 | 0.53 |
| ▸ | TTR | P02766 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24634565 | 1.00 | ACSL1 (1.00) | ACSL1ACSL6ACSL3NPC1RAB9A | |
| SCHEMBL27256207 | 0.89 | ACSL1 (0.81) | ACSL1ACSL6ACSL3NPC1RAB9A | |
| SCHEMBL27256174 | 0.89 | ACSL1 (0.81) | ACSL1ACSL6ACSL3NPC1RAB9A | |
| SCHEMBL24634626 | 0.85 | ACSL1 (1.00) | ACSL1ACSL6ACSL3NPC1RAB9A | |
| SCHEMBL27256210 | 0.82 | ACSL1 (0.82) | ACSL1ACSL6ACSL3NPC1RAB9A | |
| SCHEMBL9413588 | 0.75 | NPC1 (0.68) | ACSL1ACSL6ACSL3NPC1RAB9A | |
| SCHEMBL1749499 | 0.73 | ACSL1 (0.56) | ACSL1ACSL6ACSL3NPC1RAB9A | |
| SCHEMBL24634557 | 0.72 | ACSL1 (1.00) | ACSL1ACSL6ACSL3NPC1RAB9A | |
| SCHEMBL10614660 | 0.72 | NPC1 (1.00) | ACSL1ACSL6ACSL3NPC1RAB9A | |
| SCHEMBL1247012 | 0.72 | LMNA (0.82) | ACSL1ACSL6ACSL3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2022212568-A9 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | 1BASE PHARMACEUTICALS, LLC (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | CPT2, PC, SREBF2 | ACSL1 90/4885ACSL6 72/4885ACSL3 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.